Atorvastatin interacts with a defined set of drug classes, and is contraindicated in active liver disease and pregnancy. Screening for these before the first dose prevents almost all serious events.
Interaction classes to screen
| Class | Concern | Action |
|---|---|---|
| Metabolic inhibitors | Raised plasma levels and exaggerated effect | Reduce dose or space administration |
| Metabolic inducers | Reduced exposure and treatment failure | Review response and adjust |
| Same-target agents | Additive pharmacology | Avoid duplicate therapy |
| Agents affecting the same organ system | myalgia, raised transaminases, GI upset | Monitor and document |
Key takeaways
- Screen every new prescription against the patient's full medicine list.
- Common reactions, myalgia, raised transaminases, GI upset, are amplified by interacting drugs.
- Document the interaction check in the dispensing record.
- Re-screen whenever another long-term medicine is added.
Monitoring in practice
Most interaction risk is manageable with a scheduled review after the onset window of LDL response measurable at 4 weeks and one further check at steady state. Patients on multiple chronic medicines benefit from an annual structured medication review.
Atorvastatin at a glance
| Attribute | Detail |
|---|---|
| Drug class | HMG-CoA reductase inhibitor |
| Common brand | Lipitor |
| Licensed use | hyperlipidaemia and cardiovascular risk reduction |
| Available strengths | 10, 20, 40, 80 mg |
| Dosage form | film-coated tablet |
| Typical onset | LDL response measurable at 4 weeks |
| Duration / dosing interval | 24-hour dosing |
| Storage | below 30 °C |
